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Numerous signaling pathways and cardiac-specific tran-scription factors regulate heart development and the 
function of the adult heart.1,2 The complexity of the path-
ways involved, their multiple interactions requiring a finely 
tuned balance, and the requirement to form a complex ana-
tomical structure probably explain the rather high incidence 
of congenital heart defects (CHD) mounting up to ≈1% of 
all newborns.3 Surprisingly, the primary causes of most com-
mon abnormalities, such as atrial septal defect and ventricular 
septal defect, remain enigmatic also because only a limited 
number of CHDs follow Mendelian traits.4,5 The deficits in our 
understanding of pathogenetic events leading to CHDs illus-
trate the need to obain a comprehensive and integrated view of 
the complex mechanisms involved in cardiac morphogenesis.
Much progress has been made to identify the molecular 
events associated with pathological conditions of the heart, 
including valve abnormalities, hypertension, diabetes melli-
tus, coronary artery disease, or idiopathic cardiomyopathies. 
Researchers have characterized changes in gene activity and 
posttranslational modifications (PTMs) of specific cardiac 
proteins, contributing to impaired cardiac contractility and 
promoting pathological mitochondrial or metabolic altera-
tions.6,7 However, very few new drugs have emerged from 
such efforts, despite a rising number of patients suffering 
from heart failure. It seems likely that the prevalence of heart 
insufficiency will further increase in the future because of an 
aging population and a prolonged lifespan of cardiac patients, 
which represents a pressing need to develop new therapeutic 
approaches. On the other hand, numerous signaling pathways, 
which hold an enormous potential for therapeutic interven-
tions, have barely been investigated in the heart. It seems 
likely that this terra incognita contains novel targets, which 
allow modulation of diseases-relevant processes to counteract 
cardiac dysfunctions.
In the last decade, the PTM of proteins with the small 
ubiquitin-like modifier (SUMO) has emerged as a central 
regulatory mechanism for the control of cellular functions, in-
cluding developmental and differentiation processes. Detailed 
general reviews that cover mechanistic and functional aspects 
of SUMO signaling have been published.8,9 However, our un-
derstanding of tissue-specific functions of the SUMO system 
is still incomplete. Based on recent findings, we will give an 
overview of the heart-specific functions of the SUMO system. 
In particular, we discuss the role of SUMO conjugation and 
deconjugation in regulating heart development, metabolism, 
contractility, and protein quality control. We will also examine 
the potential involvement of the SUMO system in stress adap-
tation of the adult heart and critically evaluate the physiologi-
cal and pathological relevance.
General Features of SUMO Conjugation/
Deconjugation System
SUMOylation is a transient and reversible PTM in which 
SUMO proteins are conjugated to lysine residues of target 
proteins.8,9 In human, 4 SUMO isoforms (SUMO1, 2, 3, 
and 4) have been identified to date, which share a common 
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structure that is characterized by the evolutionary conserved 
ubiquitin-fold. The primary structure of SUMO1 shows 
≈50% sequence identity with both SUMO2 and SUMO3, 
which are very similar (with 97% of identity).10 The physi-
ological role of SUMO4, which is absent in most cell types 
and cannot be conjugated because of the lack of C-terminal 
processing (see below), is still under debate.11–13 Genetic and 
biochemical data indicate that the 3 SUMO variants SUMO 
1, 2, and 3 are likely to play partially redundant roles, al-
though distinct effects in cellular processes have been 
described.10,14,15 All SUMOs are expressed as precursor pro-
teins and have to be processed before conjugation. Similar 
to ubiquitylation, conjugation generally proceeds through 
3 reaction steps in which SUMO-activating, -conjugating, 
and -ligating (E1, E2, and E3, respectively) enzymes act se-
quentially (Figure 1). Currently, it is not entirely clear how 
substrate specificity of conjugation is achieved because only 
1 dimeric E1 enzyme (SUMO-activating enzyme 1/SUMO-
activating enzyme 2), a single E2 enzyme (ubiquitin-conju-
gating enzyme 9 [Ubc9]), and a handful of E3 ligases are 
known.8 The present view in the field is that the E3 ligases 
of the PIAS (protein inhibitors of activated STATs) family 
(PIAS1, PIAS2, PIAS3, PIAS4) and Mms21 (nonstructural 
maintenance of chromosomes element 2) homolog as well 
as RanBP2 (ras-related nuclear protein binding protein 2), 
or the human polycomb protein polycomb 2/chromobox ho-
molog 4 (hPC2/CBX4) stimulate conjugation of SUMO to 
a whole group rather than to individual target proteins. This 
concept has been termed group modification.16,17
The general function of SUMO conjugation or SUMO 
group modification involves regulation of distinct protein/
protein interactions or the organization of higher-order pro-
tein complexes.17 Attachment of SUMO can either promote or 
prevent the assembly of protein complexes. Steric hindrance 
or masking of an interaction domain are the main mechanisms 
for SUMO-mediated disassembly of a complex.18 The promo-
tion of protein interactions by SUMO conjugation is typically 
achieved through SUMO-dependent recruitment of binding 
partners, which contain distinct SUMO-binding modules 
termed SUMO-interacting motifs (SIMs)8,18 (Figure 1).
SUMO modification is reversed by SUMO-specific hydro-
lases that remove SUMO from the target through cleaving the 
isopeptide bond of a SUMO conjugate (Figure 1).8 This en-
ables a highly dynamic regulation of protein functions, making 
SUMOylation an ideal regulatory mechanism for fast cellular 
decisions. In higher vertebrates, 3 classes of SUMO-specific 
hydrolases have been defined to date. The largest and best-stud-
ied class is the ubiquitin-like protein (Ubl)–specific protease/
SUMO/sentrin-specific proteases (SENP) family, which con-
sists of 6 members: SENP1, 2, 3, 5, 6, and 7. The deSUMOylat-
ing isopeptidase class DeSI (deSUMOylating isopeptidase-1 
and deSUMOylating isopeptidase-2) and ubiquitin-specific 
protease-like 1 (USPL1) also act as SUMO-proteases but their 
substrate specificity and function is still not clear.8 Interestingly, 
most SENPs also catalyze the processing of SUMO precur-
sors, which will promote conjugation. This dual function of 
SENPs in both maturation and deconjugation of SUMO adds 
Nonstandard Abbreviations and Acronyms
AMPK adenosine monophosphate activated kinase
CHD congenital heart defect
Drp1 dynamin-related protein 1
E1, E2, E3 SUMO activating, conjugating, and ligating enzymes, respectively
GATA4/6 GATA binding protein 4/6
HDAC histone deacetylase
HIF1α hypoxia-inducible factor 1α
IR ischemia-reperfusion
KO knockout
MEF2 myocyte enhancer factor 2
Nkx2.5 Nk2 homeobox 5
PGC-1α peroxisome proliferator-activated receptor coactivator-1alpha
PIAS protein inhibitors of activated STATs
PPAR peroxisome proliferator-activator receptor
PTM posttranslational modification
ROS reactive oxygen species
SENP SUMO/sentrin-specific protease
SERCA2a sarcoplasmic/endoplasmic reticulum calcium ATPase 2a
SIRT1 sirtuin 1
SUMO small ubiquitin-like modifier
Ubc9 ubiquitin conjugating enzyme 9
UPS ubiquitin-proteasome system
Figure 1 . Pathway of small ubiquitin-like modifier (SUMO) 
conjugation/deconjugation and the SUMO-dependent 
recruitment of SUMO interacting motif (SIM)–containing 
interaction partners. SUMO is covalently attached to specific 
lysine (Lys) residues of target proteins in an enzymatic process 
that involves an E1 activating enzyme (SAE1/SAE2), a single E2 
conjugating enzyme (Ubc9), and different SUMO E3 ligases, such 
as Protein inhibitors of activated STATs (PIAS) proteins, ras-related 
nuclear protein (Ran)–binding protein 2 (RanBP2), and possibly 
others. As a result, an isopeptide bond is formed between the 
C-terminal glycine residues of SUMO and an ε-amino group of a 
Lys residue of the target protein. Attachment of additional SUMO 
moieties to internal Lys residues of SUMO induces polymeric 
chains (mainly by SUMO2/3). SUMO is deconjugated from target 
proteins by SUMO-specific isopeptidases (SUMO/sentrin-specific 
protease [SENP]). SUMO conjugates are specifically recognized 
by interaction partners that possess a specific binding module 
termed SIM (SUMO interaction motif). SAE1/2 indicates SUMO 
activating enzyme 1 and 2.
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an additional layer to the complexity of the SUMO conjugation/
deconjugation system. How these two functions are balanced 
and how target specificity of distinct SENPs is achieved has 
largely remained elusive. Moreover, their specificity toward dis-
tinct SUMO forms is not yet fully explored. The current view 
is that SENP1 possesses both processing and deconjugating ac-
tivities, mainly removing SUMO1 from substrates,19–22 whereas 
SENP2 has a lower processing activity, but is more active in 
deconjugation of both SUMO1 and SUMO2.19,23–25 SENP3 and 
SENP5 act preferentially on SUMO2/3 in both processing and 
deconjugation,26–28 whereas SENP6 and SENP7 are not effec-
tive in removing monomeric SUMOs but mainly cleave di- or 
polymeric chains of SUMO2/3, thereby editing lysine-linked 
SUMO–SUMO chains.27,29–31
Balanced SUMO conjugation/deconjugation plays a pivot-
al role in the control of many cellular processes.8,17,18,32–35 One 
clear hotspot for SUMO function is nuclear DNA transactions, 
such as chromatin organization, transcriptional processes, or 
DNA repair. Additionally, the SUMO pathway has a critical 
function in the nucleolus by regulating ribosome biogenesis. 
In addition to these well-established nuclear or nucleolar 
functions of the SUMO system, the significance of SUMO 
modifications outside the nucleus has recently been reported, 
revealing a role in the regulation of ion channel activity, plas-
ma membran receptors, or G-protein signaling, exocytosis, 
autophagy, cytoskeletal function, dynamics of mitochondria, 
mitosis, and apoptosis.32 Considering this wide spectrum of 
regulatory events, it seems likely that SUMOylation partici-
pates in pathogenic events, such as cancerogenesis.8 Indeed, 
increased expression of Ubc9 was found in different tumors,36 
and SENPs are differentially expressed in various cancer 
types. Because mitotically active cells are profoundly de-
pendent on active SUMOylation/deSUMOylation cycles, the 
SUMO system has been proposed as possible target in cancer 
therapy.37 On the other hand, post-mitotic cells, for example, 
neurons are also sensitive to abnormalities in SUMO modifi-
cation, possibly leading to neurodegeneration.8 Furthermore, 
emerging evidence points to an important role of SUMO in 
both the developing and adult heart.
Heart Development
Heart development is driven by an evolutionarily conserved 
programme that is governed by diverse signaling molecules 
and tissue-specific transcription factors.2 SUMO proteins 
have been shown to target and modulate the activity of sev-
eral critical factors involved in cardiac development, such as 
serum responsive factor, myocardin, GATA-binding protein 
(GATA)-4, Nk2 homeobox 5 (Nkx2.5), myocyte enhancer fac-
tor-2 (MEF2), Ying Yang 1 (YY1), prospero-related homeo-
box (Pro1), and T-box transcription factors-2 and -5 (TBX2, 
TBX5).38 The SUMO-dependent regulation of these specific 
factors has been described in detail39–41 but new findings in 
mouse models with alterations in the SUMO pathway provide 
a novel integrated view on SUMO function during embryonic 
development (Table). Interestingly, both hypo- or hyperSU-
MOylation because of dysfunction of either the conjugation or 
deconjugation system result in embryonic or cardiac defects, 
indicating that a tight control of the degree of SUMOylation is 
essential for normal cardiac development44,54 (Table).
Inhibition of SUMO conjugation by genetic inactivation of 
the SUMO-conjugating E2 enzyme Ubc9 causes early embry-
onic lethality in mice between embryonic stage 3.5 and em-
bryonic stage 7.5,42 demonstrating that attachment of SUMO 
is essential for embryonic viability (Table). In heterozygous 
Ubc9-mutant fibroblasts, mainly the SUMO2/3 conjugation is 
reduced,42 suggesting that SUMO2/3 conjugation is more sen-
sitive than SUMO1 to variations of Ubc9 expression during 
embryonic development. Indeed, Wang et al reported in a very 
recent publication that SUMO2 knockout (KO) mice, charac-
terized by compromized cell proliferation and increased apop-
tosis, die at about embryonic stage 10.5, whereas SUMO3 
KOs are viable.49 These findings indicate that SUMO2 is in-
dispensible for embryonic development. Despite their high 
similarity, neither SUMO1 nor SUMO3 can complement 
SUMO2 most likely because of their significantly lower 
Table.  Cardiac Phenotype After Genetic Modulation of the SUMO Conjugation/Deconjugation System in Mice
Mouse Line System Modified Cardiac Phenotype References
Ubc9 KO SUMO conjugation ↓ Embryonic lethality at early post-implantation stage (between E3.5 and E7.5) 42
Ubc9-Tg ↑ Not analyzed (more tolerant to brain ischemia) 43
SUMO1 KO ↓ Embryonic lethality, ASD/VSDs vs normal 44 vs 45, 46
αMHC-SUMO1-Tg ↑ Normal (beneficial in heart failure) 44, 47
rAAV9-SUMO1 ↑ Normal (beneficial in cardiac hypertrophy) 48
SUMO2 KO ↓ Embryonic lethality at E10.5 49
αMHC-SUMO2-Tg ↑ Premature death, cardiomyopathy of various severity with enhanced apoptosis 50
SUMO3 KO ↓ Normal 49
SENP1 KO SUMO deconjugation ↓ Embryonic lethality at E12.5–E14.5 51
rAAV9-SENP1 ↑ Dilated cardiomyopathy with mitochondrial abnormalities 52
SENP2 KO ↓ Embryonic lethality at E10, congenital heart defect 53
αMHC-SENP2-Tg ↑ ASD/VSD or cardiomyopathy/fibrosis in aged mice 54
αMHC-SENP5-Tg ↑ Dilated cardiomyopathy with mitochondrial abnormalities 55
ASD indicates atrial septal defect; E, embryonic stage; KO, knockout; α-MHC, α-myosin heavy chain; rAAV9, recombinant adeno-associated virus serotype 9; SENP, 
SUMO/sentrin-specific protease; SUMO, small ubiquitin-like modifier; Tg, transgenic; and VSD, ventricular septal defect.
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expression levels. In fact, SUMO2 mRNA levels (70%–80%) 
are substantially higher than SUMO1 (15%–20%) or SUMO3 
(2%–20%) in both embryonic and adult tissues. Accordingly, 
SUMO2 contributes the vast majority of total SUMO2/3 
proteins at both stages. Despite its critical role in embryonic 
development, the SUMO2 KO mouse line does not show a 
specific cardiac phenotype, whereas the constitutive KO of 
SUMO1 led to specific cardiac septal defects (atrial septal de-
fect and ventricular septal defect) with high penetrance.44 The 
defects in SUMO1-mutant mice were rescued by transgenic 
cardiac-specific expression of SUMO1 arguing for an im-
portant and specific function of SUMO1 conjugation during 
normal cardiac development.44 However, it is noteworthy that 
other groups failed to detect a phenotype in SUMO1 KO mice 
possibly because of differences in the genetic background and 
gene-targeting strategies.45,46
The importance of a tightly regulated level of 
SUMOylation is also underlined by the observation of cardiac 
abnormalities in mice with cardiomyocyte-specific overex-
pression of the SUMO isopeptidase SENP2 (α-myosin heavy 
chain-SENP2-transgenic),54 which decreases SUMO1 modifi-
cation essentially mimicking the lack of SUMO1. In addition, 
cardiac-specific overexpression of SUMO1 correcting defec-
tive SUMO1 conjugation in α-myosin heavy chain-SENP2-
transgenic mice rescues developmental defects and triggers 
cardiomyocyte proliferation54 (Table). In summary, these data 
demonstrate that SUMO1 and SENP2 are key regulators of 
early cardiac morphogenesis. SENP2 acts as a deSUMOylat-
ing enzyme for a whole set of substrates, including GATA4 
and other transcription factors that are critical for heart devel-
opment.2 The CHD observed in SENP2-transgenic mice might 
thus be the combined result of enforced deSUMOylation 
of a group of substrates. A prime candidate is Nkx2.5 be-
cause SENP2 was shown to inhibit Nkx2.5 transcriptional 
activity through promoting deconjugation of SUMO1.56–58 
Accordingly, a number of Nkx2.5 targets are downregulated 
in SENP2 transgenic mice, and the compound mutant SENP2-
transgenic/Nkx2.5+/− mice exhibit a more severe phenotype.54 
On the contrary, mutations of Nkx2.5 linked to CHDs show 
an altered SUMOylation pattern.56–58 Taken together, the avail-
able data suggest that SUMO1—at least partially—exerts its 
function during embryogenesis by maximizing the activity of 
Nkx2.5. Additional candidates for critical targets of SUMO1 
are serum responsive factor/myocardin or GATA4.44,59–62 It 
is worth noting that a subgroup of α-myosin heavy chain-
SENP2-transgenic mice does not develop cardiac septal 
defects, but show cardiac hypertrophy and fibrosis (cardiomy-
opathy) during aging, indicating that balanced SUMOylation 
is also important for heart function in adult animals.54 Because 
cardiac-specific overexpression of SUMO1-transgenic does 
only rescue the embryonic but not the adult heart phenotype 
of α-myosin heavy chain-SENP2-transgenic mice, it is tempt-
ing to speculate that enforced SENP2-mediated deconjugation 
of SUMO2/3 but not of SUMO1 primarily contributes to the 
adult phenotype. In support of this idea, cardiac-specific over-
expression of SENP5, which deconjugates mainly SUMO2/3 
from target proteins, does not result in embryonic heart de-
fects, but induces cardiomyopathy in adult mice.55
In contrast to the above-mentioned mutants resulting in 
decreased SUMO1- or SUMO2/3 conjugation in the heart, 
the consequences of enhanced SUMOylation for the heart 
have not yet been analyzed in great detail (Table). Ubc9 
transgenic mice were investigated in the context of brain 
ischemia, where enhanced SUMOylation protects against 
ischemic damage.43 At least in some pathological situations, 
enhanced modification by SUMO1 seems beneficial for car-
diac function because cardiac-specific SUMO1-transgenic 
expression improved heart failure.44,47 In contrast, cardiac-
specific SUMO2 overexpression induces premature death 
and severe cardiomyopathy, although no obvious embryonic 
phenotype has been described.50 SENP1 KO mice, another 
animal model for unbalanced SUMO deconjugation, exhibit 
embryonic lethality possibly because of persistent SUMO1 
conjugation of hypoxia-inducible factor 1 alpha (HIF1α), 
which triggers its subsequent degradation followed by down-
regulation of the HIF1α target gene erythropoietin and de-
fective erythropoesis.51 Furthermore, SENP2 KO mice die at 
embryonic stage 10 because of decreased cardiomyocyte pro-
liferation and defective heart formation53 (Table). Knockout 
of SENP2 in embryonic hearts results in accumulation of 
SUMO1-conjugated hPC2/CBX4 (part of polycomb repress-
ing complex 1), thereby increasing polycomb 2/chromobox 
homolog 4 occupancy on promoters of polycomb group tar-
get genes, which causes enhanced repression of GATA4 and 
GATA6, crucial regulators of cardiac development.53,63–65 It 
seems reasonable to assume that lack of SENP1 or SENP2 
activities induces hyperSUMOylation of several substrates 
but apparently only few of them are critical for cardiac devel-
opment. Moreover, orthologue, substrate, or tissue specificity 
of the SUMO proteases might play a distinctive role in proper 
SUMOylation in the embryonic heart because the phenotypes 
of SENP1 versus SENP2 mutants differ considerably.
Altogether, one might speculate that SUMO1 plays a more 
specific role in cardiac development than SUMO2/3, whereas 
in adult hearts, disturbance of both SUMO1 and SUMO2/3 
conjugation has detrimental effects. However, the specific and 
essential role of different SUMO orthologues (SUMO1 versus 
SUMO2) or various SENPs in embryogenesis has to be fur-
ther clarified in more detail by systematic analysis of cardiac-
specific KO and transgenic mouse lines.
Cardiac Metabolism
Proper cardiac function and contractility require a constant 
energy supply to fuel contraction/relaxation cycles. In the 
healthy adult, heart energy is mainly provided by oxidative 
phosphorylation, whereas cardiomyocytes in hypertrophic 
hearts or during heart failure undergo a metabolic switch and 
use mainly glucose instead of fatty acids.66
Cardiac energy homeostasis is critically regulated by per-
oxisome proliferator-activator receptors (PPAR) both under 
physiological and pathological conditions (for comprehensive 
review, see Madrazo and Kelly67 and Neels and Grimaldi68). 
The PPAR family includes 3 members: PPARα, -β, and -γ. 
Cardiomyocytes express high amounts of PPARα and -β, but 
less PPARγ.68 PPARα was first described as a master regula-
tor of genes controlling fatty acid oxidation.69 Interestingly, its 
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expression decreases in several experimental models of car-
diac hypertrophy.70–72 Conditional overexpression of PPARβ 
in adult hearts indicate that PPARβ plays a crucial role for 
the regulation of mitochondrial biogenesis and the enzymatic 
antioxidant defense system.73–75 Moreover, PPARβ promotes 
physiological cardiac remodeling.76 Based on these findings, 
PPAR agonists were proposed to be beneficial for treatment of 
heart failure. However, the currently available PPAR agonists 
show significant side effects, thereby limiting a general use.77,78
PPARs and their associated co-regulators are extensively 
regulated by PTMs, such as ubiquitylation and SUMOylation 
in different cells types. Although SUMO-dependent regula-
tion of PPARs has not been studied in heart so far (for de-
tailed review, see Wadosky and Willis79), it seems reasonable 
to assume that this type of PPAR regulation also acts in car-
diomyocytes.80,81 SUMO-modification represses the tran-
scriptional activity of PPAR isoforms by modification of the 
ligand-binding domains in PPARα and PPARγ.79,82 Additional 
SUMOylation sites for SUMO1 conjugation are present in the 
D domain of PPARα and in the activation domain of PPARγ. 
In skeletal muscle cells, SENP2-regulated deSUMOylation of 
PPARγ1 controls fatty acid oxidation and ATP production,83 
whereas SENP2 inhibits glycolysis and induces glucose oxi-
dation in mouse embryonic fibroblasts.84 In light of these 
findings, it is tempting to speculate that SUMO-dependent 
repression of PPARs play a role in the control of cardiac 
metabolism.
Peroxisome proliferator-activated receptor coactivator-
1alpha (PGC-1α), the co-activator of PPAR/RXRα (9-cis reti-
noic acid receptor α), plays a crucial role in heart physiology, 
as well as a potent regulator of mitochondrial biogenesis.85–87 
PGC-1α upregulation in long-term exercise represents a ben-
eficial adaptive mechanism by which striated muscles in-
crease the capacity of mitochondrial oxidation.87–90 PGC-1α is 
SUMOylated by the E3 SUMO ligases PIAS1 and PIAS3, re-
sulting in inhibition of its transcriptional activity by promoting 
interaction with the corepressor RIP140 (receptor-interacting 
protein 140).91 Enhanced deSUMOylation by transgenic over-
expression of SENP1 in the heart causes activation of PGC-
1α and induces cardiomyopathy.52 However, at present, it is 
not clear whether the increased activity of PGC-1α solely re-
lies on deSUMOylation of PGC-1α by SENP152 or whether 
other regulatory events participate in this phenomenon. In 
fact, SENP1 also deSUMOylates MEF2C, a member of the 
MADS-box transcription factors, which controls expression 
of PGC-1α in the heart.52 Because SUMOylation inhibits the 
activity of MEF2 factors,92–94 SENP1-mediated activation of 
MEF2C will increase PGC-1α transcription. Future experi-
ments might disclose the relative input of each pathway for 
SENP1-mediated activation of PGC-1α in transgenic mouse 
hearts.52
Notably, SUMO modification of ERK5 (extracellular 
signal-regulated kinase 5) may also contribute to SUMO-
dependent repression of both PPARs and MEF2. ERK5 is 
an atypical mitogen-activated protein kinase functioning as 
a transcriptional co-activator for PPARs and MEF2 in the 
heart.95–97 SUMOylation of ERK5, which is strongly induced 
in diabetic animals, dampens its transcriptional activity. In 
diabetic mice, this was linked to ventricular dysfunction after 
myocardial infarction.96
Acetylation/deacetylation represents a different way 
to regulate the activity of PPARs and PGC-1α. Sirtuin 1 
(SIRT1), an NAD+-dependent histone deacetylase (HDAC), 
plays an important role in cardiac metabolism.98 SIRT1 in-
creases the activity of PPARs and PGC-1α by deacetylation 
to induce fatty acid oxidation and mitochondrial biogen-
esis.99 Hence, loss of SIRT1 activity leads to dilated cardio-
myopathy in adult hearts accompanied with mitochondrial 
dysfunction and reduced mitochondrial gene expression.100 
Nevertheless, SIRT1 also controls the acetylation status of 
MEF2 transcription factors, which as outlined above regu-
late PGC-1α expression. Intriguingly, Zhao et al showed that 
MEF2 is modified by either acetylation or SUMOylation. 
Deacetylation of MEF2 by SIRT1/HDAC4 at a specific ly-
sine residue allows SUMOylation (acetylation/SUMOylation 
switch), thereby dampening MEF2 activity.101 Interestingly, 
SIRT1 itself undergoes SUMOylation at the C-terminal re-
gion (K734), which enhances its deacetylase activity at least 
2-fold.102 However, it is not clear whether SUMO modifica-
tion of SIRT1 causes a general increase in its activity or en-
hances affinity to a certain pool of substrates. On the other 
hand, SENP1 and SENP2 both interact with SIRT1, leading 
to its inactivation.102 Although this mechanism has not been 
analyzed in the heart to date, MEF2 might be activated by 
either enhanced acetylation (as a consequence of inactivated 
SIRT1 by SENP1) or by direct deSUMOlyation via SENP1, 
thereby inducing PGC-1α expression. Further experiments 
are necessary to study the relevance of SUMOylation/de-
SUMOylation in cardiac metabolism for the regulation of 
SIRT1/MEF2/PGC1-α/PPAR activity.
Adenosine monophosphate–activated protein kinase 
(AMPK) is a master regulator of cardiac metabolism (re-
viewed in Palomer et al103 and Zaha and Young104). Similar to 
SIRT1, AMPK positively regulates the PPAR/PGC-1α axis, 
leading to the activation of mitochondrial functions.103,104 
Very recently, Rubio et al demonstrated that SUMOylation is 
a novel PTM of AMPK.105 The authors show that modifica-
tion of AMPK depends on the E3 SUMO ligase PIAS4 and 
SUMO2 and propose that SUMOylation stimulates AMPK 
activity by preventing its ubiquitin-dependent degradation 
(SUMOylation/ubiquitylation switch). Because the AMPKβ1 
isoform is not modified by SUMO2, the SUMOylation/ubiq-
uitylation switch may represent a selective mechanism to acti-
vate certain isoforms of AMPK under specific conditions or in 
a cell type–specific manner. Activation of AMPK in the heart 
by SUMOylation is of outstanding interest because AMPK 
appears to act as a cardioprotective regulator in different path-
ological conditions. Modulation of the SUMOylation status 
of AMPK might thus be a future therapeutic approach to treat 
cardiac disease (ie, in hypertrophy, heart failure, ischemia/re-
perfusion [IR]).104 In summary, SUMO modification of main 
regulators, such as PPARs, PGC-1α, SIRT1, or AMPK, might 
play an important role in the control of cardiac metabolism, 
although much has to be learned to gain a comprehensive un-
derstanding of SUMOylation/deSUMOylation for metabolic 
decisions in the heart.
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Cardiac Contractility
Intracellular Ca2+ concentrations influence contraction and re-
laxation of the heart. Upon excitation, extracellular Ca2+ enters 
cardiomyocytes through L-type Ca2+ channels, promoting Ca2+ 
release from the endoplasmic reticulum (Ca2+-induced Ca2+ re-
lease).106 Relaxation occurs after removal of Ca2+ through the 
plasma membrane natrium-calcium exchangers and the sarco-
plasmic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a). 
Activity of SERCA2a is dynamically regulated by phosphol-
amban phosphorylation, which increases the ATPase activity 
of SERCA2a, resulting in enhanced Ca2+ transport into the 
endoplasmic reticulum, thereby preparing the next contrac-
tion cycle.107 Dysregulation of Ca2+ cycling and reduction of 
SERCA2a activity represent hallmarks of heart failure and are 
recognized as major pathogenic drivers in diseased hearts. As 
reviewed extensively elsewhere,6,107 Hajjar et al revealed that 
the levels of SUMO1 (but not SUMO2/3) are decreased in a 
murine heart failure model and that SERCA2a is critically and 
positively regulated by SUMO1 conjugation.47 Identification 
and mutation of the 2 major SUMOylation sites in SERCA2a 
(K480R and K585R) revealed that loss of SUMOylation sig-
nificantly decreases ATP-binding affinity and ATPase activity 
of SERCA2a, respectively. Moreover, it was proposed that 
SUMOylation of SERCA2a (similar to AMPK) prevents ubiq-
uitylation and subsequent proteasomal degradation, thereby 
increasing the stability of SERCA2a. Consistent with these 
data, elevated SUMO1 or SERCA2a levels induced by viral 
transfection increase SERCA2a activity and improve heart 
failure in mice. Importantly, SUMO1 does not improve car-
diac parameters in a heart failure model induced by SERCA2a 
downregulation, demonstrating that SERCA2a is indeed the 
key target in this pathway.
In further support of this concept, Hajjar’s group used 
a gene therapy approach to express SUMO1 and SERCA2a 
in an IR heart failure model in pigs,108 which resulted in 
functional improvements, although the increase in ejec-
tion fraction did not reach statistically significant levels. 
Nevertheless, gene delivery of SUMO1 and SERCA2a might 
play a beneficial role in human cardiac disease. Moreover, 
a potential new strategy has been recently described using 
a small molecule activator (N106) that targets SERCA2a 
SUMOylation to improve ventricular function in mice with 
heart failure.109
A more complex view of the regulation of contractility 
by SUMOylation has emerged by analyzing the cross talk of 
acetylation and SUMOylation similar to the regulation of the 
SIRT1-MEF2-PGC-1α axis as discussed earlier.110 It is known 
that HDAC inhibitors exert cardioprotective effects by pro-
moting Lys acetylation.111,112 More recent studies also uncov-
ered increased global SUMOylation (mainly by SUMO1) in 
cardiomyocytes after HDAC inhibitor treatment, which seems 
to be mediated by HDAC2.110 Because the steady state level of 
SENPs did not change after inhibition of HDAC2, increased 
SUMOylation enhanced conjugation rather than reduced 
deconjugation appears to be the primary mode of action. 
However, changes in the level of acetylation might also have 
a more direct impact on the activity of SERCA2a. Hajjar et 
al postulated that acetylation of SERCA2a113 can be reversed 
by the Class III HDAC enzyme, SIRT1.47 Future experiments 
will clarify the significance of reversible acetylation ver-
sus SUMOylation of SERCA2a or other critical targets (eg, 
MEF2) known to regulate heart contractility.
Cardiac Protein Quality Control
Protein quality control plays an essential role in regulating 
cell homeostasis by preventing accumulation of misfolded or 
damaged proteins. The protein quality control system works 
in a sequential manner with molecular chaperones repre-
senting the first defence line by refolding abnormal proteins 
and eventually disassembling protein aggregates. Failure of 
chaperone function leads to activation of 2 major pathways, 
the ubiquitin–proteasome system (UPS) and selective mac-
roautophagy, which are responsible for the removal of mis-
folded proteins.114 Recent work points to an interconnection 
of the SUMO system with the UPS for removal of misfolded 
or aggregated proteins via the SUMO-targeted E3 ubiquitin 
ligase pathway. In this pathway, the aberrant proteins are 
first polySUMOylated by specific E3 SUMO ligases of the 
tripartite motif family. PolySUMOylation serves as a sig-
nal for recognition by distinct E3 ubiquitin ligases, such as 
RNF4 or RNF111 (ring finger protein-4/111) that bind to 
the SUMO2/3 chains through tandem SUMO-interacting 
motifs, ubiquitinylate misfolded proteins, and direct them 
to UPS degradation.115–119
There is increasing evidence that misfolded proteins 
(forming the so-called preamyloid oligomers) contribute to 
the pathogenesis of cardiac disease and heart failure under 
various conditions.120–123 Work from Gupta et al indicates that 
the SUMO system triggers cardiac quality control by activat-
ing protein degradation through the proteasome system.124,125 
Knock down of the E2 SUMO conjugating enzyme Ubc9 in 
cardiomyocytes causes accumulation of protein aggregates, 
and lack of Ubc9 impairs cardiac function in a heart model of 
proteotoxicity, whereas overexpression of Ubc9 reduces for-
mation of protein aggregates by stimulation of the UPS sys-
tem. Although the underlying mechanisms are not completely 
clear yet, it is plausible that Ubc9 stimulates SUMO-targeted 
E3 ubiquitin ligase–mediated clearing of protein aggregates in 
cardiomyocytes.124,125 Ubc9-mediated SUMOylation of other 
components of the UPS or the autophagy machinery may also 
trigger protein quality control.126 The Beclin1-VPS34 (vacuolar 
protein sorting 34) complex, which serves a critical function in 
autophagosome formation, is stabilized by SUMOylation,127 
another possible mechanism by which SUMOylation might 
regulate removal of toxic protein aggregates. Understanding 
the mechanisms that determine specificity of the SUMO sys-
tem for protein aggregates might lead to novel therapeuti-
cal interventions in cardiac disease that are linked to protein 
aggregates.128–130
Cardiac Stress Adaptation
The heart uses various adaptation mechanisms to cope with 
cellular stress. However, metabolic, hypertrophic, ischemic, 
or oxidative stress responses might also lead to pathological 
adaptation, resulting in cardiac dysfunction and heart failure. 
Identification of cardioprotective factors, which prevent or re-
verse pathological adaptions, is an important goal in transla-
tional medicine.
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Enhanced cellular SUMOylation seems to play a benefi-
cial role to protect the brain during ischemia, stroke, or hiber-
nation torpor (for detailed review, see Guo and Henley131 and 
Lee and Hallenbeck132), which might represent a paradigm for 
the heart as well. Data obtained in animal models and human 
patients suggest that balanced SUMO conjugation/deconjuga-
tion is critical for cardiac stress adaptation.47,50,124,125 A benefi-
cial effect of the cardiotropic recombinant adeno-associated 
virus-SUMO1 transgene has been described in the experimen-
tal model of transverse aortic constriction, in which cardiac 
hypertrophy and heart failure is induced by pressure overload. 
Enhanced SUMOylation suppresses the hypertrophic phe-
notype in this model, and SUMO1 expression in cultivated 
cardiomyocytes inhibits hypertrophic responses.48 Although 
the full range of SUMO1 targets in the heart is not known, 
it is likely that SERCA2a is one of the relevant substrates by 
which enforced SUMO1 modification exerts its cardioprotec-
tive effects in certain pathological conditions.47
However, another mouse model with constitutive heart-spe-
cific expression of SUMO2 revealed a more complex scenario 
characterized by dose-dependent induction of hypertrophy and 
cardiomyopathy.50 Increased global SUMO2/3 conjugation 
seems to induce apoptosis via modification of calpain-2 and 
calpastatin, crucial components of the proteolytic system that 
is activated upon cell death. Increased expression of SUMO2 
represses calpastatin by inducing its breakdown, which in turn 
enhances the enzymatic activity of calpain-2 normally inhib-
ited by calpastatin.50 It is possible that the different outcomes 
of forced SUMO1 or SUMO2 expression result from modifica-
tion of distinct sets of substrates targeted by either SUMO1 or 
SUMO2. In addition, the expression level and the time course 
of expression is certainly a critical factor. Because many cellu-
lar processes require coordinated cycles of SUMO conjugation 
and deconjugation of key regulators, a supraphysiological ex-
pression level of any component of the SUMOylation system 
will most likely cause unwanted adverse effects.
The deSUMOylating enzyme SENP1 seems to play an 
important role for balancing SUMO conjugation/deconjuga-
tion in cardiomyocytes in response to hypertrophic stimuli as 
indicated by the increased expression of SENP1 in hypertro-
phic and failing hearts of human patients.52 The calcineurin-
NFAT3 (nuclear factor of activated T-cells-3) pathway, which 
is activated during cardiac hypertrophy, induces expression 
of SENP1. This might be a compensatory effect in the initial 
phase of hypertrophy, limiting the glycolytic metabolic switch 
in dysfunctional heart, because SENP1 enhances cardiac PGC-
1α expression and subsequent mitochondrial gene activation. 
However, uncontrolled mitochondrial biogenesis ultimately 
causes loss of sarcomeric structure, cardiomyopathy, and heart 
failure. Therefore, the prolonged SENP1 expression observed 
in human failing hearts might contribute to cardiac dysfunc-
tion by altering mitochondrial function.52 This conclusion is 
also supported by the finding that forced expression of SENP1 
through a virus-based approach induces dilated cardiomyopa-
thy and mitochondrial abnormalities in adult mice52 (Table).
Similar deleterious effects of enhanced SUMO deconjuga-
tion in adult heart were also observed after forced expression 
of SENP2 or SENP5 in the heart, leading to cardiomyopathies 
and cardiac dysfunction54,55 (Table). Increased expression of 
SENP5 is linked to alterations in mitochondrial dynamics and 
mitochondrial fission, which is assumed to rely on enhanced 
recruitment of mitochondria and oligomerization of the dy-
namin-related protein (DRP1).133 Several lines of evidence 
indicate that transient SUMOylation of DRP1 controls the 
dynamic association of DRP1 with mitochondria. McBride 
and co-workers proposed that SUMO1 conjugation enhanc-
es retention of DRP1 on the membrane after recruitment of 
DRP1 to mitochondria, followed by disassembly of the DRP1 
oligomer via de-SUMOylation once fission is complete.134–136 
Recently, SENP5, SENP3, and SENP2 were identified as 
SUMO deconjugases of DRP1 (Figure 2). It was proposed 
that recruitment of SENP5 to mitochondria, which normally 
occurs during mitosis, drives mitochondrial fragmentation 
by enhancing the SUMO cycle on DRP1 in concert with the 
SUMO E3 ligase MAPL (mitochondrial-anchored protein 
ligase).135–137 Furthermore, mitochondrial-anchored protein 
ligase SUMOylation of DRP1 stabilizes an endoplasmic re-
ticulum/mitochondrial platform required for cell death.138 In 
contrast, lack of SENP5 traps SUMO1-conjugated DRP1 at 
the mitochondrial membrane, ultimately leading to apoptotic 
cell death. In a cardiac-specific transgenic mouse model, Kim 
et al confirmed that forced expression of SENP5 decreases the 
level of SUMO2/3-conjugated DRP1 in the heart, which ac-
cording to their model results in enlarged mitochondria with 
several functional abnormalities and enhanced apoptotic cell 
death55 (Figure 2). Along the same line, reduced SUMO2/3 
conjugation of DRP1 mediated by SENP3 in an in vitro cel-
lular model of neuronal IR resulted in mitochondrial associa-
tion, cytochrome c release, and cellular apoptosis139,140 (Figure 
2). Again, paralogue-specific effects of different SUMO fam-
ily members might explain these discrepancies. McBride et al 
mainly focused on DRP1-SUMO1 conjugates, whereas in the 
SENP5 mouse model and in the neuronal cell culture model, 
DRP1-SUMO2/3 conjugates were studied. Conjugation of 
SUMO2/3 to DRP1 might prevent its association with mito-
chondria and cell death, whereas SUMO1 modification might 
promote residency of DRP1 at mitochondria to induce apop-
tosis. In line with this idea, neuron-specific SENP2 KO mice 
suffer from neurodegeneration via dysregulation of mitochon-
drial functions, which was attributed to removal of SUMO1 
from DRP1 by SENP2 counteracting neuronal apoptosis.141 To 
date, the available data suggest that an imbalance of SUMO 
conjugation/deconjugation affects cell functions by disturbing 
mitochondrial dynamics. Such a mechanism might be partic-
ularly relevant for the response of the heart to hypertrophic 
or ischemic stimuli, but a full understanding of the role of 
SUMO-dependent signaling in this process will require fur-
ther system-wide proteomic approaches. The data on DRP1 
also exemplify that the outcome of an unbalanced SUMO con-
jugation or deconjugation critically depends on the cell type, 
as well as the physiological or pathological context. Hence, 
lack of SUMOylation and enhanced SUMOylation may not 
necessarily cause opposing phenotypes. In fact, disruption of 
the modification-demodification cycle in either way seems to 
affect target protein function in a very similar manner.
Mitochondrial abnormalities induce not only metabolic 
alterations or cellular apoptosis but profoundly influence the 
production of reactive oxygen species (ROS). Increased ROS 
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generation from different sources plays a major role in vari-
ous cardiac pathologies, including cardiac hypertrophy and 
IR injury.142,143 In fact, ROS are a major cause of IR injury 
in heart, as well as in brain.144 Importantly, SUMO2/3 con-
jugation increases during cerebral IR injury in animal mod-
els, although it is still debated whether SUMOylation occurs 
mainly during reperfusion or already during the initial isch-
emia period.131,132,145
Several lines of evidence suggest that the dynamic regula-
tion of SUMOylation serves as a cytoprotective pathway.131,132 
For example, transgenic mice overexpressing Ubc9 show a di-
minished infarct size in the brain after focal cerebral ischemia 
when compared with control animals.43 Moreover, in hiber-
nating animals, which provide a model of natural tolerance to 
ischemia, massive SUMOylation is observed in brain.146 The 
mechanisms that trigger the dynamics of SUMOylation in isch-
emia and reoxygenation and elicit cytoprotection are not yet 
fully understood. However, there is accumulating evidence that 
the stability and activity of the enzymatic components of the 
SUMO system are tightly regulated by the cellular redox sta-
tus. One key example is the SUMO isopeptidase SENP3 which 
is one of the most prominent genes upregulated on the very 
first day after traumatic brain injury.147 Under basal conditions, 
SENP3 is rapidly degraded via the UPS.148 Mild oxidative 
stress by oxidation of cysteine 243 and 274 in SENP3 protects 
SENP3 from degradation, thus enhancing SENP3-mediated 
deSUMOylation events149,150 (Figure 3). In contrast, SENP3 ac-
tivity is inhibited by oxidation of the catalytic cysteine residue 
during severe oxidative stress (Cys532)149,150 (Figure 3). Hence, 
SENP3 deSUMOylates SUMO2/3 targets, such as the coactiva-
tor p300, during mild oxidative stress, thereby increasing p300 
binding to HIF1α and enhancing its transcriptional activity. 
In contrast, strong oxidative stress prevents p300 from deSU-
MOylation and HIF1α activation (Figure 3). The biphasic re-
dox sensing of SENP3 may also contribute to cardiac IR injury, 
but clear experimental evidence is still missing. In contrast, the 
cardiac function of SENP1 is better understood. IR injury in 
human and mouse hearts and in isolated cardiomyocytes leads 
to increased SENP1 levels, and heterozygous SENP1+/− mice 
develop larger myocardial infarct lesion than control animals, 
indicating that SENP1 limits IR injury.151,152 Because SENP1-
mediated de-SUMOylation stabilizes HIF1α under hypoxic 
conditions51 and elevated HIF1α protects against cardiac IR 
injury, deSUMOylation of HIF1α by SENP1 or SENP3 might 
be critical for cardioprotection.152,153 Furthermore, low levels 
of ROS activate SENP1 similar to SENP3, whereas high ROS 
levels induce SENP1 inactivation (Figure 3). SENP1 acts also 
as a factor to develop tolerance to hypoxia, contributing to hy-
poxia-driven vascular endothelial growth factor expression and 
angiogenesis in endothelial cells,154,155 and protects against hy-
drogen peroxide–induced cell death, whereas its depletion en-
hances apoptosis in vitro.156,157 It is, therefore, obvious that the 
simple model of a beneficial role of enhanced SUMOylation 
Figure 2. Effect of differential SUMOylation of dynamin-
related protein (Drp1) on apoptotic cell death in various cell 
types. Mitochondrial fission is achieved through mitochondrial 
recruitment and oligomerization of the DRP1. Transient 
SUMOylation controls the dynamic association of DRP1 with 
mitochondria affecting both mitosis and apoptosis. SENP5, 
SENP3, and SENP2 were identified as SUMO deconjugases 
of DRP1 in different cell types. Silencing of SENP5 in COS-7 
or HeLa cells increases modification of DRP1 by SUMO1 in 
a process mediated by the E3 SUMO ligase mitochondrial-
anchored protein ligase (MAPL), which enhances binding to 
mitochondria, eventually resulting in mitochondrial fragmentation 
and cellular apoptosis. Cardiac-specific overexpression of 
SENP5 in mouse hearts decreases DRP1-SUMO2/3 levels, 
which in turn promotes association of de-SUMOylated DRP1 
to mitochondria, thereby inducing apoptosis. Similarly, cortical 
neurons subjected to in vitro ischemia re-express SENP3 after 
re-oxygenation. Induced deconjugation of DRP1-SUMO2/3 
increases the residence time of DRP1 at mitochondria and 
promotes neuronal apoptosis. In contrast, the cytoplasmic 
isoform of SENP2 (SENP2S) exerts neuroprotective effects by 
deconjugating DRP1-SUMO1. SUMO1 conjugation of DRP1 
might thus enhance mitochondrial association and promote 
fragmentation and apoptosis, whereas SUMO2/3 conjugation 
seems to decrease mitochondrial localization of DRP1 and 
reduce cell death. SENP indicates SUMO/sentrin-specific 
protease; and SUMO, small ubiquitin-like modifier.
Figure 3 . Regulation of hypoxia-inducible factor 1 alpha 
(HIF1α) by small ubiquitin-like modifier (SUMO) conjugation/
deconjugation in mild versus strong oxidative stress. The 
SUMOylation status of HIF1α is highly redox-sensitive and 
regulated by the relative activities of SUMO conjugating (SAE2, 
Ubc9) versus deconjugating enzymes (SENP1, SENP3). Mild 
oxidative stress inhibits both SAE2 and Ubc9 enzymes by 
reversible covalent crosslinking of catalytic cysteine (Cys) 
residues. In contrast, oxidation of a noncatalytic Cys residue 
protects both SENP1 and SENP3 from degradation under the 
same conditions. SENP1 directly deSUMOylates HIF1α and 
increases its stability, whereas SENP3 deSUMOylates p300, 
enhancing its co-activator function towards HIF1α. In contrast, 
SENP1 and SENP3 are inactivated or degraded during strong 
oxidative stress, resulting in enhanced SUMOylation of both 
p300 and HIF1α, which in turn inhibit HIF1α activity and stability, 
respectively. SAE2 indicates SUMO activating enzyme 2; SENP, 
SUMO/sentrin-specific protease; and Ubc9, ubiquitin conjugating 
enzyme 9.
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after post-ischemic injury needs to be refined because, as dis-
cussed earlier, deSUMOylation by SENP1 can be protective 
as well. Instead, based on both cardiac and noncardiac studies, 
a more complex picture emerges, indicating that timely con-
trolled and finely balanced SUMOylation of specific substrates 
but not bulk conjugation/deconjugation is critical. Moreover, 
a general note of caution should be raised when it comes to 
the interpretation of SENP overexpression or depletion phe-
notypes. SENPs function not only in demodification, but also 
in processing of the SUMO precursors.158 Depletion of a given 
SENP, therefore, does not necessarily lead to enhanced con-
jugation in all cases, but may also inhibit conjugation. The 
consequence of SENP depletion on modification of a given 
substrate must, therefore, always be experimentally validated.
Changes in the cellular redox status not only affect the de-
conjugating enzymes, but also influence the SUMO conjuga-
tion system in a dose-dependent way. Moderate doses of ROS 
inhibit global SUMOylation by reversible covalent cross-
linking of the catalytic cysteine residues of SUMO-activating 
enzyme 2 and Ubc9 enzymes,159 which might potentially con-
tribute to decreased SUMOylation events induced by mild ox-
idative stress in the heart (Figure 3). In contrast to the global 
effect on SUMOylation after oxididation of catalytically rel-
evant Cys residues, PTMs of Ubc9 distinctively modulate its 
affinity toward specific substrates.129,130 Hypoxia has recently 
been shown to redirect Ubc9 to a subset of substrates, includ-
ing CBP or Elk-1, thus limiting their transcriptional activity 
by enhanced SUMOylation. Targeting of Ubc9 to these sub-
strates is directed through SIRT1-mediated deacetylation of 
lysine 65, which is triggered in hypoxic cells.130 These data 
highlight the dynamics of PTMs of the main actors of the 
SUMO conjugation system, modulating SUMO-dependent 
regulatory mechanisms under various stress conditions. It is 
certainly of crucial importance to determine the relevance of 
these pathways for homeostatic and pathological regulatory 
processes in the heart.
The SUMOylation target SIRT1 does not only play an im-
portant role in the cardiac metabolism but also acts as a car-
dioprotective and adaptive factor under different cardiac stress 
conditions (for detailed review, see Kwon and Ott160, Chong 
et al161, and Yang et al162). Nucleocytoplasmic shuttling is es-
sential to target SIRT1 into the nucleus where it exerts antioxi-
dant and antiapoptotic functions. In the aging heart, nuclear 
translocation of SIRT1 is impaired during ischemic stress, 
hindering adaptive responses.163 SUMOylation of SIRT1 in-
creases its deacetylase activity, which is essential for adapt-
ing to genotoxic stress.102 At present, it is not known whether 
SUMOylation regulates the nuclear versus cytoplasmic local-
ization of SIRT1 or increases the activity of SIRT1 by other 
means. Similarly, the dominant form of SIRT1-SUMOylation 
in the heart (SUMO1- or SUMO2/3-conjugation) has not been 
identified. On the other hand, SIRT1 activity is regulated by 
SENP1 and SENP2,162 and oxidative and genotoxic stress 
lead to increased interaction with SENP1 inducing deSU-
MOylation and subsequent inactivation of SIRT1.102 Further 
research focusing on the interplay of acetylation/deacetylation 
and SUMOylation/deSUMOylation events will open new in-
sights into the complex machinery controlling stress respons-
es in the heart.
Concluding Remarks and Future Perspectives
Several key findings in the last few years have unravelled an 
important role of the SUMO system for organ function un-
der physiological and pathological conditions. Current evi-
dence suggest that SUMO1 maintains normal cell physiology 
in the brain, whereas SUMO2/3 is involved in cellular stress 
responses.8,164 Enhanced global SUMOylation (mainly by 
SUMO2/3) exerts neuroprotective effects in IR injury, highlig-
tening the potential therapeutic value of the SUMO system. In 
contrast, the role of SUMOylation in cardiovascular system 
is just emerging. Unfortunately, very little is known about 
the exact function of SUMO1 versus SUMO2/3 in the heart 
and their specific cellular targets. In the past, it has been chal-
lenging to identify and analyze endogenous SUMO targets 
because of their low abundance, but novel mass spectrometry 
techiques allow highly sensitive, proteome-wide identifica-
tion of SUMO targets in tissue culture and animal models,128 
which will help to define the SUMO proteome in cardiac tis-
sues under physiological and pathological settings. The spray 
or group modification theory of SUMOylation predicts that 
a set of functionally related and spatially linked proteins are 
simultanously regulated by SUMO.165 Therefore, it will be a 
challenge to distinguish functionally relevant SUMO targets 
from less relevant byproducts in a given cellular setting. The 
developmental master regulators GATA4, Nkx2.5, and MEF2, 
as well as key regulators in the adult heart (SERCA2a, PPARs, 
PGC-1α, SIRT1, AMPK, DRP1, and HIF1α), might already 
represent the most significant SUMO targets, but it seems very 
likely that additional important target proteins will be dis-
closed. Moreover, several contradictory results have been pub-
lished, indicating the needs to conduct careful system-wide 
biochemical approaches in established animal models. We 
are confident that a comprehensive understanding of SUMO 
functions in the heart under physiological and pathological 
conditions will eventually result in novel SUMOylation-based 
therapeutic strategies to combat heart diseases.
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